Capmatinib for MET Exon 14–Mutated or MET-Amplified NSCLC

MET exon 14 skipping mutations and MET gene amplifications occur in 3% to 4% and 1% to 6%, respectively, of patients with non–small-cell lung cancer (NSCLC). Preliminary data demonstrated promising efficacy of the highly selective MET-receptor inhibitor capmatinib in patients with MET-dysregulated NSCLC.

Now, investigators have conducted an industry-funded, multicohort, phase II trial (GEOMETRY mono-1) to evaluate the use of capmatinib (400 mg twice daily) in 364 NSCLC patients with a MET exon 14 skipping mutation or MET amplification.

Results were as follows:

• Among treatment-naive patients with MET exon 14 skipping mutations, the overall response rate (ORR; the primary endpoint) was 68%, and the median duration of response was 12.6 months; am…